Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Splits Out Specialty Dx as Reporting Segment

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it has formed a new reporting segment for its specialty diagnostics operations.

The firm will now have three financial reporting units: Analytical Technologies, Specialty Diagnostics, and Laboratory Products and Services. The firm formerly reported under two segments: Analytical Technologies and Laboratory Products and Services.

"Following our acquisition of Phadia, our Specialty Diagnostics business has significant scale — with more than $2 billion in revenues— and greater access to a number of high-growth end markets," Thermo Fisher Scientific President and CEO Marc Casper said in a statement. "Our new reporting structure provides investors with better visibility into our company."

The Specialty Diagnostics segment contains five businesses — anatomical pathology, clinical diagnostics, and microbiology, which all were previously part of the Analytical Technologies Segment; immunoDiagnostics (formerly Phadia); and the healthcare market channel, which was part of the Laboratory Products and Services segment.

Thermo Fisher also provided certain historical financial results reflecting the new segment reporting structure.

For the second quarter ended July 2, 2011, Thermo would have reported revenues of $929.2 million for the Analytical Technologies segment, $569.5 million for Specialty Diagnostics, and $1.53 billion for Laboratory Products and Services. When it reported its Q2 results in late July, Thermo posted revenues of $1.28 billion for the Analytical Technologies segment and $1.76 billion for its Laboratory Products and Services segment.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more